SEARCH:   Advanced

Blood, 15 June 2007, Vol. 109, No. 12, pp. 5136-5142. Prepublished online as a Blood First Edition Paper on March 7, 2007; DOI 10.1182/blood-2006-11-056754. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2006-11-056754v1 109/12/5136    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by DeAngelo, D. J Articles by Larson, R. A. Search for Related Content PubMed PubMed Citation Articles by DeAngelo, D. J Articles by Larson, R. A. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted November 13, 2006 Accepted February 13, 2007 Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: cancer and leukemia group B study 19801 Daniel J DeAngelo*, Daohai Yu, Jeffrey L. Johnson, Steven E. Coutre, Richard M. Stone, Alison T. Stopeck, Jon P. Gockerman, Beverly S. Mitchell, Frederick R. Appelbaum, and Richard A. Larson Dept of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States CALGB Statistical Center, Duke University Medical Center, Durham, NC, United States Stanford University School of Medicine, Stanford, CA, United States Arizona Cancer Center, Tucson, AZ, United States Duke University Medical center, Durham, NC, United States University of North Carolina, Chapel Hill, NC, United States Fred Hutchinson Cancer Research Center, Seattle, WA, United States University of Chicago, Chicago, IL, United States * Corresponding author; email: ddeangelo{at}partners.org. Nelarabine (506U78) is a soluble pro-drug of 9--D-arabinofuranosylguanine (ara-G), a deoxyguanosine derivative. We treated 26 patients with T-cell acute lymphoblastic leukemia (T-ALL) and 13 with T-cell lymphoblastic lymphoma (T-LBL) with nelarabine. All patients were refractory to at least one multi-agent regimen or had relapsed after achieving a complete remission. Nelarabine was administered on an alternate day schedule (days 1, 3, 5) at 1.5 g/m2/day. Cycles were repeated every 22 days. The median age was 34 years (range, 16-66); 32 (82%) patients were male. The rate of complete remission was 31% (95% CI: 17%, 48%) and the overall response rate was 41% (95% CI: 26%, 58%). The principal toxicity was grade 3 or 4 neutropenia and thrombocytopenia, occurring in 37% and 26% of patients, respectively. There was only one grade 4 adverse event of the nervous system, which was a reversible depressed level of consciousness. The median disease free survival (DFS) was 20 weeks (95% CI: 11, 56) and the median overall survival was 20 weeks (95% CI: 13, 36). The one-year overall survival was 28% (95% CI: 15%, 43%). Nelarabine is well tolerated, and has significant anti-tumor activity in relapsed or refractory T-ALL and T-LBL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: V. Gandhi, C. Tam, S. O'Brien, R. C. Jewell, C. O. Rodriguez Jr, S. Lerner, W. Plunkett, and M. J. Keating Phase I Trial of Nelarabine in Indolent Leukemias J. Clin. Oncol., March 1, 2008; 26(7): 1098 - 1105. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020